Preclinical and Phase I Results of Decitabine in Combination with Midostaurin (PKC412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy2013Vol. 33(12), pp. 1341–1352
Citations Over TimeTop 10% of 2013 papers
Casey Williams, Suman Kambhampati, Warren Fiskus, Jo Wick, Catherine Dutreix, Siddartha Ganguly, Omar S. Aljitawi, Ruben Reyes, Allan Fleming, Sunil Abhyankar, Kapil N. Bhalla, Joseph P. McGuirk
Abstract
The in vitro combination of DAC and MS is synergistically active against FLT3-ITD mutations expressing AML cells. In a clinical setting, the combination of sequentially administered DAC followed by MS is possible without significant unexpected toxicity, but the concurrent administration of DAC and MS led to pulmonary toxicity after only a few doses. On the basis of these results, additional studies exploring the sequential combination of untreated AML in elderly patients are warranted to further evaluate this combination at the MTD.
Related Papers
- → KIT Inhibitor Midostaurin Exhibits a High Rate of Clinically Meaningful and Durable Responses in Advanced Systemic Mastocytosis: Report of a Fully Accrued Phase II Trial(2010)52 cited
- → Synergistic Activity of the MCL-1 Inhibitor S63845 with Midostaurin in Preclinical Human Models of FLT3-ITD Mutated Acute Myeloid Leukemia (AML)(2019)
- → Clinical observation of decitabine combined with CIG regimen in induction therapy for acute myeloid leukemia(2019)
- → Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients(2019)
- → Successful Management of Acute Myeloid Leukemia Patient with ASXL1 and CEBPA Gene Mutations by a Combination of Decitabine and CAG Regimen: A Case Report(2024)